Search

Displaying results 5031 - 5040 of 8698 in total
  1. Drug

    LP-2307

    go.drugbank.com/drugs/DB17470
    Experimental

    LP-2307 is an investigational allogeneic large multivalent immunogen (LMI) vaccine developed by Avanir. It was investigated for melanoma.

  2. Drug

    BHV-1310

    go.drugbank.com/drugs/DB22674
    Experimental

    BHV-1310 is a IgG<sub>1,2,4</sub> selective degrader being investigated for the treatment of Grave's disease.

  3. Drug

    Toluene

    go.drugbank.com/drugs/DB11558
    InvestigationalVet approved

    It is a mono-substituted benzene derivative used in veterinary medicine as a treatment for various parasites in dogs and cats.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  4. Drug

    AMB-301

    go.drugbank.com/drugs/DB18094
    Experimental

    AMB-301 is an AAV gene therapy delivering E-selectin.[L48101] It is under investigation for the treatment of Buerger disease.

  5. Drug

    Col-Treg

    go.drugbank.com/drugs/DB18451
    Experimental

    Col-Treg is an autologous T-cell therapy comprising type I regulatory T-cells specific for human type II collagen.[A261635]

    Synonyms: Purified autologous type 1 regulatory T lymphocytes specific for human type II collagen
  6. Drug

    XTL-001

    go.drugbank.com/drugs/DB05405
    Investigational

    XTL001 is an investigational monoclonal antibody (MAb) product developed by XTL Biopharmaceuticals to evaluate the safety profile and antiviral activity of the compound in patients chronically infected

  7. Drug

    AZD 3355

    go.drugbank.com/drugs/DB05404
    Investigational

    AZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.

    Categories: GABA-A Receptor Agonists
  8. Drug

    ALGRX 1207

    go.drugbank.com/drugs/DB06482
    Experimental

    ALGRX 1207 entered clinical trials for cutaneous neuropathic pain, such as chemotherapy-induced neuropathy, in 2006. It was being developed by Anesiva, but trials have halted.

  9. Drug

    Talmapimod

    go.drugbank.com/drugs/DB05412
    Investigational

    Talmapimod is the first-generation oral p38 MAP kinase inhibitor developed by Scios. It has shown to be effective to cure inflammatory diseases such as Rheumatoid Arthritis.

  10. Drug

    Noscapine

    go.drugbank.com/drugs/DB06174
    Approved

    Categories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP3A Inhibitors